gemcitabine has been researched along with nocodazole in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
de Lima Ferreira, LP; de Melo Rêgo, MJB; de Moraes Gomes, PAT; de Siqueira, LRP; Leite, ACL | 1 |
Cuneo, KC; Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Tanska, DM; Zabludoff, SD | 1 |
Carnevalli, LS; Dunlop, CR; Fernández, SBQ; Jodrell, DI; Johnson, TI; Kottmann, D; Lau, A; Minteer, CJ; Richards, FM; Wallez, Y | 1 |
1 review(s) available for gemcitabine and nocodazole
Article | Year |
---|---|
Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Disease Progression; Drug Delivery Systems; Drug Discovery; Humans; Intracellular Signaling Peptides and Proteins; Neoplasms; Thiazoles; Thiazolidines; Thiosemicarbazones | 2019 |
2 other study(ies) available for gemcitabine and nocodazole
Article | Year |
---|---|
Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin B1; Deoxycytidine; DNA Damage; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mitosis; Nocodazole; Pancreatic Neoplasms; Thiophenes; Urea | 2016 |
Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach.
Topics: Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; HeLa Cells; High-Throughput Screening Assays; Humans; MCF-7 Cells; Neoplasms; Nocodazole; Piperazines; Pyridines; Small Molecule Libraries; Time Factors; Tubulin Modulators | 2021 |